Based on these preclinical data, a phase II trial (NCT01761747) was designed to study FGFR1 amplification and mRNA expression as predictive markers for ponatinib sensitivity in NSCLC and SCLC patients. Here, FGFR1 is linked to small cell lung carcinoma.